Analysis of the role and efficacy of EIKANCE 0.01% atropine sulfate eye drops and its application in the prevention and control of myopia in children

0.01% atropine sulfate eye drops (EIKANCE) is a low-concentration atropine preparation, mainly used for the prevention and control of myopia, especially in children and adolescents. It has significant application value. Atropine is a non-selective anticholinergic drug that inhibits the accommodation response of the eye and reduces ciliary muscle contraction, thereby delaying excessive axial elongation. This low-concentration eyedrop not only retains the myopia prevention and control effect of the drug, but also minimizes the common side effects of high-concentration atropine, such as mydriasis, photophobia, and accommodative paralysis. EIKANCE’s mechanism of action is clinically considered to be effective in delaying the progression of myopia in children and reducing the risk of high myopia.

In the prevention and control of myopia in children, 0.01%Atropine sulfate eye drops are mainly used for patients with mild to moderate myopia, especially children whose eye axis continues to grow. Multiple clinical studies have shown that long-term regular use of low-concentration atropine can significantly slow down the speed of axial lengthening and diopter deepening. Compared with traditional methods such as wearing glasses or orthokeratology lenses, the advantage of atropine eye drops is that its pharmacological effect can directly interfere with the growth mechanism of the eyeball, thereby controlling the progression of myopia at the source. In addition, low-concentration eye drops have little impact on daily vision, and patients have better adaptability.

In terms of specific use, EIKANCEIt is generally recommended to put one drop in both eyes before going to bed every night and continue to use it for more than a year to observe the obvious effect. Parents and doctors need to closely monitor children's axial changes and refractive index progression, and be aware of minor eye irritation or transient photophobia that may be caused by the drug. Children with glaucoma, iritis or other eye diseases should use it with caution under the guidance of a doctor. Long-term follow-up data show that low-concentration atropine eye drops are safer in children, with a low incidence of side effects, mostly mild reversible symptoms.

In addition to directly controlling axial growth, EIKANCE also has the potential to improve visual quality and delay complications associated with high myopia. High myopia is often accompanied by complications such as retinal breaks and macular degeneration, and early intervention can significantly reduce these risks. Studies have shown that children who continued to use low-concentration atropine eye drops experienced statistically significant improvements in axial growth and refractive error, which has important implications for the long-term health of children's vision.

It is worth noting that EIKANCE is not a panacea. The prevention and control of myopia still requires comprehensive management, including scientific eye use, outdoor activities, reasonable work and rest, and regular review. When formulating a medication plan, doctors will make individual adjustments based on the child's age, myopia progression rate, family history, and changes in the axial length of the eye. If necessary, it can be used in conjunction with orthokeratology lenses or other intervention methods to achieve the best effect.

In short,0.01%Atropine Sulfate Eye DropsEIKANCEAs a low-concentration atropine preparation, it provides a scientific, safe and effective drug choice for the prevention and control of myopia in children. It is expected to reduce the incidence of high myopia by slowing down the elongation of the eye axis and the deepening of the diopter, while the side effects are mild and controllable. In the future, with the accumulation of more long-term clinical data, EIKANCE is expected to become a standardized drug program for the prevention and control of myopia in children and adolescents, providing parents and doctors with a reliable intervention method.

Keyword tags:

Atropine sulfate eye drops, efficacy, myopia prevention and control, children's application, mechanism of action, usage plan, safety, comprehensive management

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997187/